Emma Prevot

Emma Prevot

Auto-generated profile, based on publicly available information

Emma Prevot

University of Oxford , Department of Statistics , Oxford , UK

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
EPEmma Prevot
Emma Prevot
CSCameron Shand
Cameron Shand
FIFor Alzheimer’S Disease Neuroimaging Initiative
For Alzheimer’S Disease Neuroimaging Initiative
NONeil Oxtoby
Neil Oxtoby
Background: Alzheimer's disease (AD) exhibits substantial clinical and biological heterogeneity, complicating efforts in treatment and intervention development. While new computational methods offer insights into AD subtyping and disease staging, the reproducibility of these subtypes across datasets remains understudied, particularly concerning the robustness of subtype definitions when validated on diverse databases. Objective: This study evaluates the robustness of the AD progression subtypes identified by the Subtype and Stage Inference (SuStaIn) algorithm on a larger and more diverse cohort. Methods: We extracted T1-weighted MRI data for 5444 subjects from ANMerge, OASIS, and ADNI datasets, forming four independent cohorts. Each cohort was analyzed with SuStaIn under two conditions: one using the full cohort, including cognitively normal controls, and another excluding controls to test subtype robustness. Results: Results confirm the three primary atrophy subtypes identified in earlier studies: Typical, Cortical, and Subcortical, as well as the emergence of rare and atypical AD variants such as posterior cortical atrophy. Notably, each subtype displayed varying robustness to the inclusion of controls, with certain subtypes, like the Subcortical subtype, more influenced by cohort composition. Conclusions: This investigation underscores SuStaIn's reliability for defining stable AD subtypes and suggests its utility in clinical stratification for trials and diagnosis. However, our findings also highlight the need for improved dataset ethnic and demographic diversity, particularly in terms of ethnic representation, to enhance generalizability and support broader clinical application.

7 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EPEmma Prevot
Emma Prevot
DHDieter A. Haering
Dieter A. Haering
LGLaura Gaetano
Laura Gaetano
RSRussell T. Shinohara
Russell T. Shinohara
CHChris Holmes
Chris Holmes
HGHabib Ganjgahi
Habib Ganjgahi
Image derived phenotypes (IDPs) harmonization from Magnetic Resonance Imaging (MRI) data is essential for reducing scanner-induced, non-biological variability and enabling accurate multi-site analysis. Existing methods like ComBat, while widely used, rely on linear assumptions and explicit scanner IDs - limitations that reduce their effectiveness in real-world scenarios involving complex scanner effects, non-linear biological variation, or anonymized data. We introduce BARTharm, a novel harmonization framework that uses Image Quality Metrics (IQMs) instead of Scanner IDs and models scanner and biological effects separately using Bayesian Additive Regression Trees (BART), allowing for flexible, data-driven adjustment of IDPs. Through extensive simulation studies, we demonstrate that IQMs provide a more informative and flexible representation of scanner-related variation than categorical Scanner IDs, enabling more accurate removal of non-biological effects. Leveraging this and its ability to model complex relationships, BARTharm, consistently outperforms ComBat across a range of challenging scenarios, including model misspecification and confounded scanner-biological relationships. Applied to real-world datasets, BARTharm successfully removes scanner-induced bias while preserving meaningful biological signals, resulting in stronger, more reliable associations with clinical outcomes. Overall, we find that BARTharm is a robust, data-driven improvement over traditional harmonization approaches, particularly suited for modern, large-scale neuroimaging studies.

1 January 2026 in Statistical Applications in Genetics and Molecular Biology
Verified
Journal Article
Open access
EPEmma Prevot
Emma Prevot
RTRory Toogood
Rory Toogood
FPFilippo Pagani
Filippo Pagani
PKPaul D. W. Kirk
Paul D. W. Kirk
Cluster analyses of high-dimensional data are often hampered by the presence of large numbers of variables that do not provide relevant information, as well as the perennial issue of choosing an appropriate number of clusters. These challenges are frequently encountered when analysing omics datasets, such as in molecular precision medicine, where a key goal is to identify disease subtypes and the biomarkers that define them. Here we introduce an annealed variational Bayes algorithm for fitting high-dimensional mixture models while performing variable selection. Our algorithm is scalable and computationally efficient, and we provide an open source Python implementation, VBVarSel . In a range of simulated and real biomedical examples, we show that VBVarSel outperforms the current state of the art, and demonstrate its use for cancer subtyping and biomarker discovery.